Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2011

01-10-2011

Monozygotic Twin Pair Showing Discordant Phenotype for X-linked Thrombocytopenia and Wiskott–Aldrich Syndrome: a Role for Epigenetics?

Authors: David Buchbinder, Kari Nadeau, Diane Nugent

Published in: Journal of Clinical Immunology | Issue 5/2011

Login to get access

Abstract

Despite our increasing characterization of the molecular basis for many primary immunodeficiency states, significant heterogeneity in clinical and immunological phenotype exists. Epigenetic alterations have been implicated in the pathogenesis of immune dysregulation and may provide a unique paradigm to help us understand the phenotypic heterogeneity in primary immunodeficiency. The occurrence of X-linked thrombocytopenia (XLT) and Wiskott–Aldrich syndrome (WAS) in monozygotic twins is a rare occurrence which allows for the exploration of epigenetic alterations and associated phenotypic heterogeneity. We describe a pair of monozygotic twin brothers with a missense mutation in the WAS gene consistent with reduced expression of the WAS protein, a XLT phenotype, and a good prognosis. Despite this genotype and anticipated mild phenotype in both twins, a discordant phenotype has evolved in which one twin demonstrates asymptomatic thrombocytopenia and the other symptomatic thrombocytopenia, infectious complications, and autoimmunity. Characterization of the potential epigenetic contribution to the spectrum of XLT and WAS is described and the implications of these findings are discussed.
Literature
2.
go back to reference Lim MS, Elenitoba-Johnson K. The molecular pathology of primary immunodeficiencies. J Mol Diagn. 2004;6:59–83.PubMedCrossRef Lim MS, Elenitoba-Johnson K. The molecular pathology of primary immunodeficiencies. J Mol Diagn. 2004;6:59–83.PubMedCrossRef
3.
go back to reference Morange M. The relations between genetics and epigenetics: a historical point of view. Ann N Y Acad Sci. 2002;981:50–60.PubMedCrossRef Morange M. The relations between genetics and epigenetics: a historical point of view. Ann N Y Acad Sci. 2002;981:50–60.PubMedCrossRef
4.
go back to reference Holiday R. Epigenetics: a historical overview. Epigenetics. 2006;1:76–80.CrossRef Holiday R. Epigenetics: a historical overview. Epigenetics. 2006;1:76–80.CrossRef
5.
go back to reference Geha RS, Notarangelo LD, Casanova J-L, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;120:776–94.PubMedCrossRef Geha RS, Notarangelo LD, Casanova J-L, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;120:776–94.PubMedCrossRef
6.
go back to reference Buckley RH. Variable phenotypic expression of mutations in genes of the immune system. J Clin Invest. 2005;115:2974–6.PubMedCrossRef Buckley RH. Variable phenotypic expression of mutations in genes of the immune system. J Clin Invest. 2005;115:2974–6.PubMedCrossRef
7.
go back to reference Meda F, Folci M, Baccarelli A, et al. The epigenetics of autoimmunity. Cell Mol Immunol. 2011;8:226–36.PubMedCrossRef Meda F, Folci M, Baccarelli A, et al. The epigenetics of autoimmunity. Cell Mol Immunol. 2011;8:226–36.PubMedCrossRef
8.
go back to reference Hewagama A, Richardson B. The genetics and epigenetics of autoimmune disease. J Autoimmun. 2009;33:3–11.PubMedCrossRef Hewagama A, Richardson B. The genetics and epigenetics of autoimmune disease. J Autoimmun. 2009;33:3–11.PubMedCrossRef
9.
go back to reference Erlich M, Sanchez C, Shao C, et al. ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity. 2008;41:253–71.CrossRef Erlich M, Sanchez C, Shao C, et al. ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity. 2008;41:253–71.CrossRef
10.
go back to reference Erlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol. 2003;109:17–28.CrossRef Erlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol. 2003;109:17–28.CrossRef
11.
go back to reference Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott–Aldrich syndrome. Blood. 2009;113:6288–95.PubMedCrossRef Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott–Aldrich syndrome. Blood. 2009;113:6288–95.PubMedCrossRef
12.
go back to reference Ochs HD, Filipovich AH, Veys P, et al. Wiskott–Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2009;15:84–90.PubMedCrossRef Ochs HD, Filipovich AH, Veys P, et al. Wiskott–Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant. 2009;15:84–90.PubMedCrossRef
13.
go back to reference Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115:3231–8.PubMedCrossRef Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010;115:3231–8.PubMedCrossRef
14.
go back to reference Gulacsy V, Freiberger T, Shcherbina A, et al. Genetic characteristics of eighty-seven patients with the Wiskott–Aldrich syndrome. Mol Immunol. 2011;48:788–92.PubMedCrossRef Gulacsy V, Freiberger T, Shcherbina A, et al. Genetic characteristics of eighty-seven patients with the Wiskott–Aldrich syndrome. Mol Immunol. 2011;48:788–92.PubMedCrossRef
15.
go back to reference Thompson LJ, Lalloz M, Layton DM. Unique and recurrent WAS gene mutation in Wiskott–Aldrich syndrome and X-linked thrombocytopenia. Blood Cells Mol Dis. 1999;25:218–26.PubMedCrossRef Thompson LJ, Lalloz M, Layton DM. Unique and recurrent WAS gene mutation in Wiskott–Aldrich syndrome and X-linked thrombocytopenia. Blood Cells Mol Dis. 1999;25:218–26.PubMedCrossRef
16.
go back to reference Zhu Q, Watanabe C, Liu T, et al. Wiskott–Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90:2680–9.PubMed Zhu Q, Watanabe C, Liu T, et al. Wiskott–Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997;90:2680–9.PubMed
17.
go back to reference Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott–Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104:4010–9.PubMedCrossRef Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott–Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104:4010–9.PubMedCrossRef
18.
go back to reference Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456–64.PubMedCrossRef Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456–64.PubMedCrossRef
19.
go back to reference Schindelhauer D, Weiss M, Hellebrand H, et al. Wiskott–Aldrich syndrome: no strict genotype–phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product. Hum Genet. 1996;98:68–76.PubMedCrossRef Schindelhauer D, Weiss M, Hellebrand H, et al. Wiskott–Aldrich syndrome: no strict genotype–phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product. Hum Genet. 1996;98:68–76.PubMedCrossRef
20.
go back to reference Fillat C, Espanol T, Oset M, et al. Identification of WASP mutations in 14 Spanish families with Wiskott–Aldrich syndrome. Am J Med Genet. 2001;100:116–21.PubMedCrossRef Fillat C, Espanol T, Oset M, et al. Identification of WASP mutations in 14 Spanish families with Wiskott–Aldrich syndrome. Am J Med Genet. 2001;100:116–21.PubMedCrossRef
21.
go back to reference Yu GP, Chiang D, Song SJ, et al. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol. 2009;131:240–53.PubMedCrossRef Yu GP, Chiang D, Song SJ, et al. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol. 2009;131:240–53.PubMedCrossRef
22.
go back to reference Nadeau KC, Callejas A, Wong WB, et al. Idiopathic neutropenia of childhood is associated with Fas/FasL expression. Clin Immunol. 2008;129:438–47.PubMedCrossRef Nadeau KC, Callejas A, Wong WB, et al. Idiopathic neutropenia of childhood is associated with Fas/FasL expression. Clin Immunol. 2008;129:438–47.PubMedCrossRef
23.
go back to reference Nguyen KD, Vanichsarn C, Fohner A, et al. Selective deregulation in chemokine signaling pathways of CD4 + CD25(hi)CD127(lo)/(−) regulatory T cells in human allergic asthma. J Allergy Clin Immunol. 2009;123:933–9.PubMedCrossRef Nguyen KD, Vanichsarn C, Fohner A, et al. Selective deregulation in chemokine signaling pathways of CD4 + CD25(hi)CD127(lo)/(−) regulatory T cells in human allergic asthma. J Allergy Clin Immunol. 2009;123:933–9.PubMedCrossRef
24.
go back to reference Forsyth K, Seshadri R, Matthews C, Heddle R. Wiskott–Aldrich in identical twins: abnormality of CD4 and CD8 positive lymphocytes. Aust NZ J Med. 1988;18:73–6.CrossRef Forsyth K, Seshadri R, Matthews C, Heddle R. Wiskott–Aldrich in identical twins: abnormality of CD4 and CD8 positive lymphocytes. Aust NZ J Med. 1988;18:73–6.CrossRef
25.
go back to reference Xie H, Wang M, de Andrade A, et al. Genome-wide quantitative assessment of variation in DNA methylation patterns. Nucleic Acids Res. 2011;39:4099–108.PubMedCrossRef Xie H, Wang M, de Andrade A, et al. Genome-wide quantitative assessment of variation in DNA methylation patterns. Nucleic Acids Res. 2011;39:4099–108.PubMedCrossRef
26.
go back to reference Ushijima T, Watanabe N, Okochi E, et al. Fidelity of the methylation pattern and its variation in the genome. Genome Res. 2003;13:868–74.PubMedCrossRef Ushijima T, Watanabe N, Okochi E, et al. Fidelity of the methylation pattern and its variation in the genome. Genome Res. 2003;13:868–74.PubMedCrossRef
27.
go back to reference Pearce EL. Making sense of inflammation, epigenetics, and memory CD8+ T-cell differentiation in the context of infection. Immunol Rev. 2006;211:197–202.PubMedCrossRef Pearce EL. Making sense of inflammation, epigenetics, and memory CD8+ T-cell differentiation in the context of infection. Immunol Rev. 2006;211:197–202.PubMedCrossRef
28.
go back to reference McCall CE, Yoza B, Liu T, et al. Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun. 2010;2:395–405.PubMedCrossRef McCall CE, Yoza B, Liu T, et al. Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun. 2010;2:395–405.PubMedCrossRef
29.
go back to reference Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses. 2009;73:770–80.PubMedCrossRef Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses. 2009;73:770–80.PubMedCrossRef
30.
go back to reference Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol. 2010;14:505–10.PubMedCrossRef Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol. 2010;14:505–10.PubMedCrossRef
31.
go back to reference Mack GS. Epigenetic cancer therapy makes headway. JNCI. 2006;98:1443–4.PubMed Mack GS. Epigenetic cancer therapy makes headway. JNCI. 2006;98:1443–4.PubMed
Metadata
Title
Monozygotic Twin Pair Showing Discordant Phenotype for X-linked Thrombocytopenia and Wiskott–Aldrich Syndrome: a Role for Epigenetics?
Authors
David Buchbinder
Kari Nadeau
Diane Nugent
Publication date
01-10-2011
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2011
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-011-9561-3

Other articles of this Issue 5/2011

Journal of Clinical Immunology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine